| Pneumococcal vaccines |
The 23-valent pneumococcal polysaccharide vaccine is recommended for women with certain chronic health conditions. The 13-valent pneumococcal vaccine (PCV13) is recommended for women of immunocompromised status. PCV13 vaccine should only be provided to women when benefits outweigh risks. |
| Yellow fever |
Yellow fever vaccine is generally not recommended for pregnant women, but physicians should balance risks and benefits and provide the vaccine where travel, epidemics, or other exposure cause benefits to outweigh risks. |
| Hepatitis A |
Recommended for women with increased risk of hepatitis A acquisition or complications, if not previously vaccinated. |
| Hepatitis B |
Recommended for at-risk pregnant women based on behavioral or travel history or certain health conditions. |
| Anthrax |
Recommended only where risk of exposure is high. At-risk pregnant women should receive anthrax vaccine adsorbed and 60 days of antimicrobial treatment. |
| Japanese encephalitis |
Limited data on the safety, immunogenicity, and efficacy of the inactivated vaccine. The vaccine should be considered when outbreak, travel, or another exposure situation may pose a threat to the health of the mother and fetus and the potential benefit outweighs risk. |
| Rabies |
May be used where otherwise recommended. Given the risks associated with inadequate management, the vaccine is not contraindicated in pregnancy for post-exposure prophylaxis. |
| Polio |
Inactivated poliovirus vaccine is indicated in outbreak situations, for travel to polio-endemic areas, or where exposure cannot be avoided, and when the benefits outweigh the risks. Oral poliovirus vaccine is contraindicated in pregnancy. |
| Cholera |
Targeted vaccination of high-risk groups in cholera outbreaks and endemic areas, including groups vulnerable to severe disease (such as pregnant women), where vaccination is not otherwise contraindicated. |
| Tick-borne encephalitis |
Indicated for use in pregnant women where incidence of disease is high (>5 cases/100,000 population per year). Risks and benefits should be weighed in areas where incidence is low. |
| Meningococcal conjugate (MenACWY and MenB recombinant) |
Indicated for travelers to endemic regions and in outbreak situations. The serogroup B vaccine should be deferred and provided to pregnant women only when the benefits outweigh the risks. |
| Smallpox |
Small but serious potential risk to fetus associated with vaccination. The vaccine should not be provided to pregnant or periconceptual women except when they are at high risk of contracting the disease, given the severity of disease means that benefits outweigh risks. |
| Typhoid |
Inactivated vaccine (Vi polysaccharide) recommended for pregnant women only when clearly indicated (outbreak or where risk of exposure is high). Live vaccines (Ty21a) are contraindicated in pregnancy. |
